Pharmaceuticals - Belarus

  • Belarus
  • Belarus is projected to witness a substantial revenue growth in the Pharmaceuticals market, reaching an impressive US$269.30m by the year 2024.
  • Amongst the various sectors within the market, Oncology Drugs stands out as the largest, with a projected market volume of US$46.75m in the same year.
  • Looking ahead, the industry is expected to display a steady annual growth rate of 4.48%, resulting in a market volume of US$335.20m by 2029.
  • In comparison to other countries globally, United States is set to generate the highest revenue, with a staggering US$630.30bn in 2024.
  • These numbers highlight the significant potential and importance of the Pharmaceuticals market for Belarus.
  • Belarus has seen a significant increase in pharmaceutical research and development, making it a hub for innovative drug discovery.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Belarus, a country located in Eastern Europe, has been experiencing a significant growth in its pharmaceuticals market.

Customer preferences:
Belarusian customers have been demanding more affordable and accessible medicines, which has led to an increase in the consumption of generic drugs. In addition, there has been a growing demand for medicines that treat chronic diseases such as cardiovascular diseases, diabetes, and cancer.

Trends in the market:
One of the major trends in the Belarusian pharmaceuticals market is the increasing focus on research and development. Domestic companies are investing more in R&D to develop new drugs and improve the quality of existing ones. This has led to a rise in the number of clinical trials conducted in the country. Another trend is the growing popularity of e-pharmacies, which offer online ordering and delivery of medicines. This has made it easier for customers to access medicines, especially in rural areas.

Local special circumstances:
Belarus has a state-controlled healthcare system, which means that the government plays a significant role in regulating the pharmaceuticals market. The government sets prices for medicines and also provides subsidies for certain categories of medicines. In addition, the government has been implementing policies to promote the local production of medicines, which has led to the growth of domestic pharmaceutical companies.

Underlying macroeconomic factors:
Belarus has a stable economy with a high level of human development. The country has a well-educated workforce and a good infrastructure, which has made it an attractive destination for foreign investment in the pharmaceuticals sector. In addition, the country's membership in the Eurasian Economic Union has facilitated the trade of pharmaceuticals with other member states, which has boosted the growth of the market.In conclusion, the Belarusian pharmaceuticals market has been growing due to the increasing demand for affordable and accessible medicines, the focus on research and development, the popularity of e-pharmacies, the state-controlled healthcare system, and the underlying macroeconomic factors.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)